Baxter International Inc.
$19.97B- Market cap
- $12.50B
- Debt
- +$9.44B
- Cash
- −$1.97B
Capital structure 57% equity / 43% debt · EV / Revenue 1.78x · EV proxy / EBITDA proxy 29.68x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BAX stock price at discount vs BMY $24.18 current versus $58.77 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMY's multiple
Implied fair value · at BAX's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Multiple discount
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 57% equity / 43% debt · EV / Revenue 1.78x · EV proxy / EBITDA proxy 29.68x
Capital structure 74% equity / 26% debt · EV / Revenue 3.43x
BMY carries the larger enterprise value at $165.13B against $19.97B; BAX trades on the lower EV / Revenue multiple (1.78x vs 3.43x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BAXTER INTERNATIONAL INC. · implied price per share
Bear
-$0.03
Base
$2.03
Bull
$5.72
BRISTOL-MYERS SQUIBB COMPANY · implied price per share
Bear
$59.11
Base
$72.93
Bull
$92.88
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Medtronic plc
BAX vs MDT
STRYKER CORP
BAX vs SYK
Edwards Lifesciences Corporation
BAX vs EW
Johnson & Johnson
BAX vs JNJ
Pfizer Inc.
BAX vs PFE
Merck & Co., Inc.
BAX vs MRK
AbbVie Inc.
BAX vs ABBV
Eli Lilly and Company
BAX vs LLY
Amgen Inc.
BAX vs AMGN
Gilead Sciences, Inc.
BAX vs GILD
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.